Real-world testing of serum lactate dehydrogenase among patients with metastatic colorectal cancer in the United States.

ABSTRACT:

Background

Serum lactate dehydrogenase (LDH) is a potential prognostic biomarker of outcomes in patients with metastatic colorectal cancer (mCRC). This retrospective, observational study assessed real-world LDH testing patterns and LDH as a prognostic factor for overall survival (OS) in US patients receiving chemotherapy for mCRC.

Methods

Patients with mCRC who initiated first-line chemotherapy between January 1, 2016, and November 30, 2022, were selected from a nationwide de-identified Electronic Health Record-derived database. LDH value was categorized based on laboratory reference ranges. The prognostic relationship between pretreatment LDH value and OS was assessed using Kaplan-Meier and multivariate Cox proportional-hazards models.

Results

Of 15 329 adult patient

SUBMITTER: Lenz HJ 

PROVIDER: S-EPMC12265455 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature